Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Viral Load Reductions Persist With Less Efavirenz for HIV

The virologic responses with reduced-dose efavirenz at 48 weeks have proven durable out to 96 weeks, ENCORE1 study results show.

Published
07 November 2014
From
Medscape (requires free registration)
Ground-breaking research in Spain may be key to curing HIV

SPANISH scientists have embarked on pioneering clinical trials to find out whether HIV can be cured with stem cells from umbilical cords. Only 1% of umbilical cords have the right genetic mutation to enable blood extracted from them to wipe out HIV – a mutation known as the CCR5 Delta 32.

Published
07 November 2014
From
Think Spain
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Tenofovir Alafenamide (TAF)-Based Single Tablet Regimen for HIV

Gilead Sciences, Inc. today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational, once-daily single tablet regimen containing elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide (TAF) 10 mg (E/C/F/TAF) for the treatment of HIV-1 infection in adults.

Published
07 November 2014
From
Gilead press release
Early Initiation of Combo Antiretrovirals Gaining Support

Evidence continues to support the initiation of combined antiretroviral therapy soon after HIV infection, researchers report. In fact, the likelihood of the CD4/CD8 ratio normalizing was almost three times greater if antiretroviral therapy was initiated within 6 months of HIV infection than if it was delayed for more than 6 months, according to John Thornhill, MD, from Imperial College London in the United Kingdom, and his team.

Published
07 November 2014
From
Medscape (requires registration)
NIH Trial Tests Very Early Anti-HIV Therapy in HIV-Infected Newborns

​A new clinical trial is exploring whether giving anti-HIV therapy soon after birth to infants who became infected with HIV in the womb leads to remission of the virus, enabling the children eventually to stop treatment for an extended time period. The trial aims to build on the case of the 'Mississippi Baby'.

Published
05 November 2014
From
National Institute of Allergy and Infectious Diseases (NIAID) press release
Researchers pinpoint exactly where each building block sits in HIV

Scientists at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany and collaborators from Heidelberg University, in the joint Molecular Medicine Partnership Unit, have obtained the first structure of the immature form of HIV at a high enough resolution to pinpoint exactly where each building block sits in the virus. The study, published online today in Nature, reveals that the building blocks of the immature form of HIV are arranged in a surprising way.

Published
04 November 2014
From
Medical Xpress
Immune cells proposed as HIV hideout don't last in primate model

The type of immune cell called macrophages, which have been proposed as a 'sanctuary site' of HIV in the brain and other organs, and as a possible cause of HIV-related brain impairment, don't live long enough to serve as reservoirs of HIV, a study in PLoS Pathogens finds.

Published
04 November 2014
From
EATG
Efavirenz compromises hormonal contraceptive implant

The widely prescribed non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz substantially reduces levels of the hormonal contraceptive levonorgestrel, a component of a progesterone contraceptive implant widely used in

Published
03 November 2014
By
Keith Alcorn
Do emtricitabine and lamivudine have similar virological efficacy when used in first-line HIV therapy?

First-line antiretroviral regimens containing emtricitabine have superior virological efficacy to combinations containing lamivudine when combined with tenofovir and either nevirapine or efavirenz, Dutch investigators report in the online

Published
03 November 2014
By
Michael Carter
Injectable rilpivirine shows promise in phase I trials – but may work better for anal than vaginal sex

A phase one dose-finding and safety study in humans of TMC278 LA, a long-acting, injectable formation of the antiretroviral (ARV) drug rilpivirine, found that a single

Published
01 November 2014
By
Gus Cairns

Filter by country